Erianin induces apoptosis and pyroptosis via MAPK/ERK and PI3K/Akt pathways and synergizes with anlotinib in anaplastic thyroid carcinoma

Qiaonan Zhang, Minghan Qiu, Jiawei Liu, Zhanhua Gao, Yin Liu, Yayun Wang, Ruxue Liu, Zhen Yang, Jie Hao, Ming GaoFrontiers in Pharmacology 2025 · DOI

Abstract

Collectively, our study demonstrates that erianin exerts potent anti-tumor activity in ATC by simultaneously inhibiting the MAPK/ERK and PI3K/Akt signaling pathways, thereby inducing apoptosis and GSDME-dependent pyroptosis. Furthermore, the synergistic interaction between erianin and anlotinib significantly enhances therapeutic efficacy. These findings position erianin as a promising candidate for the treatment of ATC, offering novel therapeutic insights and supporting further clinical investigations.

Introduction

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal malignancies known, with a median survival of only 4 to 6 months. It is notoriously resistant to conventional therapies like chemotherapy and radiation. While targeted therapies (like BRAF inhibitors) exist, they only work for a subset of patients, and resistance develops rapidly. There is a desperate need for "multi-hit" therapeutic strategies that can bypass existing resistance mechanisms. This study explores whether erianin—a bibenzyl compound derived from the Dendrobium orchid—can fill this gap by targeting the fundamental signaling pathways that drive ATC progression.

Mechanism of Action: Dual Pathway Inhibition and Pyroptosis

Transcriptomic analysis and functional validation revealed that erianin exerts its anti-tumor effects by simultaneously suppressing two critical signaling axes: the MAPK/ERK and PI3K/Akt pathways. These pathways are primary drivers of ATC proliferation and drug resistance. By inhibiting these "engines" of tumor growth, erianin triggers a "double-edged sword" of cell death.

Unlike many conventional agents that primarily induce apoptosis, erianin also triggers pyroptosis, a form of inflammatory cell death. This study identifies GSDME (Gasdermin E) as the key mediator of this process in ATC. While many cancers utilize GSDMD for pyroptosis, ATC specifically overexpresses GSDME. Erianin exploits this by activating caspase-3, which then cleaves GSDME to form membrane pores, leading to cell swelling and lysis. This induction of pyroptosis is significant as it may stimulate the body's immune response against the tumor.

Results: Potent In Vitro Growth Inhibition

The anti-proliferative effects of erianin were evaluated across three ATC cell lines: CAL62, C643, and BHT101. Erianin demonstrated remarkable potency, with IC50 values reaching the nanomolar range (e.g., 76.27 nM in CAL62 cells at 96 hours).

Erianin inhibits ATC cell proliferation and colony formation in a dose-dependent manner.

As illustrated in Figure 5, erianin treatment significantly reduced cell viability and inhibited the ability of ATC cells to form colonies across all tested lines. These effects were dose-dependent and accompanied by morphological changes consistent with both apoptosis and pyroptosis.

Therapeutic Synergy with Anlotinib

To enhance clinical relevance, the study explored the combination of erianin with anlotinib, a multi-target kinase inhibitor already used in clinics. The combination showed strong synergism, with Combination Index (CI) values consistently below 0.9, indicating that the two drugs work better together than the sum of their parts.

Synergistic effects of erianin and anlotinib in vitro and in vivo.

In vivo validation using a CAL62 xenograft mouse model confirmed these findings. The combination therapy resulted in significantly greater reductions in tumor volume and weight compared to either drug alone, without increasing systemic toxicity. This synergy suggests that adding erianin could allow for lower, more effective doses of anlotinib, potentially reducing side effects while increasing efficacy.

Conclusion

This study identifies erianin as a potent multi-hit therapeutic agent for ATC. By simultaneously targeting the MAPK/ERK and PI3K/Akt pathways and inducing both apoptosis and GSDME-dependent pyroptosis, erianin overcomes traditional resistance mechanisms. Its synergistic interaction with anlotinib further highlights its potential for clinical translation. Future research will focus on identifying the direct molecular targets of erianin and exploring its impact on the tumor immune microenvironment.

Summary updated

Abstract

Collectively, our study demonstrates that erianin exerts potent anti-tumor activity in ATC by simultaneously inhibiting the MAPK/ERK and PI3K/Akt signaling pathways, thereby inducing apoptosis and GSDME-dependent pyroptosis. Furthermore, the synergistic interaction between erianin and anlotinib significantly enhances therapeutic efficacy. These findings position erianin as a promising candidate for the treatment of ATC, offering novel therapeutic insights and supporting further clinical investigations.
BibTeX
@inproceedings{zhang2025erianin,
  author = {Qiaonan Zhang and Minghan Qiu and Jiawei Liu and Zhanhua Gao and Yin Liu and Yayun Wang and Ruxue Liu and Zhen Yang and Jie Hao and Ming Gao},
  title = {{Erianin induces apoptosis and pyroptosis via MAPK/ERK and PI3K/Akt pathways and synergizes with anlotinib in anaplastic thyroid carcinoma}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1596873},
}
Figure